Ocean Biomedical, Inc. is a publicly traded biotech research and development company incorporated in Delaware, with no specific operational or financial figures provided in the excerpt.

# Ocean Biomedical, Inc. Company Summary

**Overview:**
Ocean Biomedical, Inc. is a Delaware-incorporated company that is publicly traded on the NASDAQ Stock Market under the ticker symbols **OCEA** (common stock) and **OCEAW** (warrants).

**Business Focus:**
The company’s primary activities involve biomedical research and development. Specific details regarding their products, services, or research areas are not provided in the excerpt.

**Financial Information:**
- **Number of Customers:** Not specified.
- **Number of Employees:** Not specified.
- **Revenue:** Not specified.
- **Net Income:** Not specified.

**Additional Details:**
- The company is classified as an emerging growth company and a smaller reporting company.
- As of June 30, 2024, the market value of the company’s voting and non-voting common stock held by non-affiliates was approximately **$5,473,915.52**, based on a closing stock price of **$1.22**.
- Shares outstanding as of March 31, 2025, totaled **166,010,805**.
- The company is filing its annual report (Form 10-K) to disclose detailed corporate governance, executive compensation, ownership, and auditor information, primarily through incorporation by reference from its Proxy Statement filed on February 26, 2025.

*Note: The provided document is an SEC filing amendment primarily related to corporate governance and controls disclosures; it does not include specific operational, customer, employee, revenue, or income figures.*

Ocean Biomedical, Inc. is a biopharmaceutical company focused on developing innovative therapies for oncology, fibrosis, and infectious diseases through strategic collaborations with research institutions.


# Ocean Biomedical, Inc. Overview

**Company Structure:**
- Ocean Biomedical, Inc. was incorporated in June 2021 and underwent a business combination leading to the current structure.
- As of November 24, 2024, Ocean Biomedical has **7 full-time employees**, including three with Ph.D. or M.D. degrees.

**Business Focus:**
- Ocean Biomedical is a biopharmaceutical company dedicated to bridging the gap between medical research and patient solutions.
- The company collaborates with research universities and medical centers to license inventions and develop them into products targeting diseases with significant unmet medical needs.

**Current Product Pipeline:**
1. **Oncology**
   - **OCX-253**: Monoclonal antibody targeting Chi3l1 for treating Non-Small Cell Lung Cancer (NSCLC).
   - **OCX-410**: Bispecific antibody targeting Chi3l1 and PD-1, also for NSCLC.
   - **OCX-909**: Bispecific antibody targeting Chi3l1 and CTLA-4 for Glioblastoma Multiforme (GBM).
   
2. **Fibrosis**
   - **OCF-203**: Small molecule targeting Chit1 for treating Idiopathic Pulmonary Fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS).

3. **Infectious Diseases**
   - **ODA-570**: Vaccine candidate against malaria.
   - **ODA-611**: Monoclonal antibody targeting PfGARP for symptomatic malaria.
   - **ODA-579**: Small molecule targeting PfGARP for symptomatic malaria.

**Financial Overview:**
- The company reported a **net loss of $114.7 million** for the fiscal year ended December 31, 2023.
- Accumulated deficit amounts to **$196.1 million** as of December 31, 2023.
- Ocean Biomedical has not yet generated any revenue from product sales and does not anticipate immediate income.

**Strategic Collaborations:**
- Ocean Biomedical's active assets are primarily licensed from Brown University and Rhode Island Hospital.
- The company operates with an innovative licensing structure, granting equity in programs to the discovering institutions and researchers involved.

**Market Landscape:**
- The company operates in an intensely competitive biopharmaceutical landscape, facing competition from both large pharmaceutical companies and emerging biotech firms.
- With a focus on proprietary technologies and partnerships, Ocean Biomedical seeks to develop differentiated therapeutics in oncology, fibrosis, and infectious diseases.

**Future Outlook:**
- The company anticipates moving several product candidates into clinical trials within the next 12 to 18 months.
- Plans to continuously assess and optimize the development pathways for each product candidate.



Ocean Biomedical, Inc.

10-K / April 29, 2025

10-K / November 25, 2024

10-K / April 29, 2025

Ocean Biomedical, Inc. Company Summary